Daiichi Sankyo announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company&r...
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application f...
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) announced a definitive agreement for Lilly to acquire Mor...
Merck known as MSD outside of the United States and Canada, and Orion Corporation announced that notice has been provided of the mutual exercise of...
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today anno...
The status is based on preclinical data and data from an ongoing phase 1/2 study for BNT324/DB-1311; preliminary phase 1/2 clinical data showed anti-tu...
Mika Health, a global digital therapeutics developer specializing in meeting the needs of cancer patients, in collaboration with AstraZenecaand Daiichi S...
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloi...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
LIXTE Biotechnology Holdings, Inc. a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer I...
Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence T...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clini...
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC a...
© 2024 Biopharma Boardroom. All Rights Reserved.
